FLUDARABINE PHOSPHATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1991)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 1X9VK9O1SC
Parent Compound: FLUDARABINE

Structure
InChI Key GIUYCYHIANZCFB-FJFJXFQQSA-N
Smile Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H13FN5O7P
Molecular Weight 365.21
AlogP -1.72
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 4.0
Polar Surface Area 186.07
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 24.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR DNA polymerase (alpha/delta/epsilon) inhibitor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Lyase
- - - 130.9 -
Enzyme Transferase
- - - - 11.13-25.25
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -13.12--4.37

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Lymphoma, Mantle-Cell 3 D020522 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Bone Marrow Failure Disorders 3 D000080983 ClinicalTrials
Anemia, Aplastic 3 D000741 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Multiple Myeloma 3 D009101 ClinicalTrials
Leukemia, Megakaryoblastic, Acute 3 D007947 ClinicalTrials
Waldenstrom Macroglobulinemia 3 D008258 ClinicalTrials
Anemia, Refractory, with Excess of Blasts 3 D000754 ClinicalTrials
Leukemia, Myelomonocytic, Chronic 3 D015477 ClinicalTrials
Leukemia, Erythroblastic, Acute 3 D004915 ClinicalTrials
Leukemia, Monocytic, Acute 3 D007948 ClinicalTrials
Leukemia, Myelomonocytic, Acute 3 D015479 ClinicalTrials
Myeloproliferative Disorders 3 D009196 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Anemia, Refractory 3 D000753 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Myeloproliferative Disorders 3 D009196 ClinicalTrials
Myelodysplastic Syndromes 3 D009190 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Anemia, Aplastic 3 D000741 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 D015464 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Leukemia, Prolymphocytic, T-Cell 2 D015461 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Leukemia, Lymphoid 2 D007945 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Crohn Disease 2 D003424 ClinicalTrials
Neuroblastoma 2 D009447 ClinicalTrials
Scleroderma, Systemic 2 D012595 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Primary Myelofibrosis 2 D055728 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Leukemia, Prolymphocytic, B-Cell 2 D054403 ClinicalTrials
Leukemia, Myelomonocytic, Juvenile 2 D054429 ClinicalTrials
Sezary Syndrome 2 D012751 ClinicalTrials
Mycosis Fungoides 2 D009182 ClinicalTrials
Histiocytosis 2 D015614 ClinicalTrials
Lymphoma, T-Cell, Peripheral 2 D016411 ClinicalTrials
Immunoblastic Lymphadenopathy 2 D007119 ClinicalTrials
Burkitt Lymphoma 2 D002051 ClinicalTrials
Polycythemia Vera 2 D011087 ClinicalTrials
Lymphoma, Large-Cell, Anaplastic 2 D017728 ClinicalTrials
Lymphoma, B-Cell, Marginal Zone 2 D018442 ClinicalTrials
Skin Neoplasms 2 D012878 ClinicalTrials
Myelodysplastic-Myeloproliferative Diseases 2 D054437 ClinicalTrials
Shwachman-Diamond Syndrome 2 D000081003 ClinicalTrials
Wiskott-Aldrich Syndrome 2 D014923 ClinicalTrials
Anemia, Sickle Cell 2 D000755 ClinicalTrials
Anemia, Diamond-Blackfan 2 D029503 ClinicalTrials
Severe Combined Immunodeficiency 2 D016511 ClinicalTrials
Osteopetrosis 2 D010022 ClinicalTrials
Fanconi Anemia 2 D005199 ClinicalTrials
Lupus Erythematosus, Systemic 2 D008180 ClinicalTrials
Hemoglobinuria 2 D006456 ClinicalTrials
Neoplasms, Plasma Cell 2 D054219 ClinicalTrials
Leukemia, Prolymphocytic 2 D015463 ClinicalTrials
Peritoneal Neoplasms 2 D010534 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Kidney Neoplasms 2 D007680 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Graft vs Host Disease 2 D006086 ClinicalTrials
Leukemia, Large Granular Lymphocytic 2 D054066 ClinicalTrials
Leukemia-Lymphoma, Adult T-Cell 2 D015459 ClinicalTrials
Granuloma, Lethal Midline 2 D006103 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Primary Myelofibrosis 2 D055728 ClinicalTrials
Neoplasm Metastasis 1 D009362 ClinicalTrials
Blast Crisis 1 D001752 ClinicalTrials
Prostatic Neoplasms 1 D011471 ClinicalTrials
Head and Neck Neoplasms 1 D006258 ClinicalTrials
Leukemia, Plasma Cell 1 D007952 ClinicalTrials
Leukemia, Biphenotypic, Acute 1 D015456 ClinicalTrials
Neoplasm Metastasis 1 D009362 ClinicalTrials
Carcinoma, Renal Cell 1 D002292 ClinicalTrials
Liver Neoplasms 1 D008113 ClinicalTrials
Prostatic Neoplasms 1 D011471 ClinicalTrials
Leukemia, Biphenotypic, Acute 1 D015456 ClinicalTrials
Multiple Sclerosis 1 D009103 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Infections and infestations
14.72
Blood and lymphatic system disorders
12.15
General disorders and administration site conditions
9.24
Nervous system disorders
7.64
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
7.33
Injury, poisoning and procedural complications
6.56
Respiratory, thoracic and mediastinal disorders
6.15
Vascular disorders
5.09
Gastrointestinal disorders
4.38
Immune system disorders
4.15
Investigations
3.88
Skin and subcutaneous tissue disorders
3.37
Hepatobiliary disorders
3.23
Renal and urinary disorders
2.48
Metabolism and nutrition disorders
2.08
Cardiac disorders
2.06

Cross References

Resources Reference
ChEBI 63599
ChEMBL CHEMBL1096882
DrugBank DB01073
DrugCentral 1189
EPA CompTox DTXSID2023060
FDA SRS 1X9VK9O1SC
Human Metabolome Database HMDB15206
PharmGKB PA449655
PubChem 30751
SureChEMBL SCHEMBL3511
ZINC ZINC000003927870
CONTENTS